Daniel Aillaud‐De‐Uriarte
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Daniel Aillaud‐De‐Uriarte has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Luis A. Hernández Flores
Houston Methodist Hospital
2 shared publications - Alberto Aparicio
The University of Texas Medical Branch
1 shared publication - Alejandro Cendejas-Higuera
Medical Doctor, Christus Muguerza Hospital, Monterrey, Nuevo Leon, Mexico
1 shared publication - Eric Acosta-Marquez
Universidad Anáhuac Puebla
1 shared publication - Haire Manzano-Cortes
Hospital Ángeles Puebla
1 shared publication - Jesús J. Rosales‐De‐La‐Rosa
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán México City México
1 shared publication
Latest Publications
- 10 June 2026
- Published by Wiley in World Journal of Surgery
- Vol. 50 (8) , 2203-2204
Beyond Feasibility: The Ethics of Same‐Day Discharge After Colectomy
- 10 June 2026
- Published by Wiley in World Journal of Surgery
- Vol. 50 (8) , 2203-2204
Beyond Feasibility: The Ethics of Same‐Day Discharge After Colectomy
Blaming the Patient: The Ethical Failures of Responsibility‐Based Liver Transplant Policy in Alcohol Use Disorder
Responsibility continues to shape how many transplant programs evaluate liver transplantation for patients with Alcohol Use Disorder (AUD), even in settings where the traditional 6‐month abstinence rule has been abandoned. This article argues that using past drinking to lower transplant priority, or to break ties between candidates, is ethically mistaken and clinically harmful. Appeals to personal responsibility often misrepresent the nature of addiction and overestimate the degree of knowledge and control individuals possess when harmful drinking patterns begin and escalate. Early onset of alcohol use, trauma, and psychiatric comorbidity frequently constrain the range of meaningful options available long before transplantation becomes relevant. When these histories are treated primarily as evidence of blameworthy behavior, stigma is reinforced and patients may have fewer incentives to be honest about relapse risk or struggles in treatment. The article examines several influential arguments that defend the use of responsibility in transplant allocation and explains why they fail in practice. It then proposes an alternative framework. Allocation should rely on forward‐looking criteria that are relevant to clinical outcomes and fairness, including medical urgency, expected benefit, engagement in treatment, reliability in follow‐up care, and the presence of social support. These considerations can be assessed more transparently than retrospective judgments about deservingness and avoid penalizing patients for circumstances that contributed to their illness. The article concludes by considering the implications for transplant committees. Policies should reward engagement in care and support recovery rather than rely on retrospective moral judgments about past behavior. Doing so strengthens trust between clinicians and patients, improves adherence to treatment, and allocates a scarce resource on grounds that are ethically relevant to the success of transplantation.
Blaming the Patient: The Ethical Failures of Responsibility‐Based Liver Transplant Policy in Alcohol Use Disorder
Responsibility continues to shape how many transplant programs evaluate liver transplantation for patients with Alcohol Use Disorder (AUD), even in settings where the traditional 6‐month abstinence rule has been abandoned. This article argues that using past drinking to lower transplant priority, or to break ties between candidates, is ethically mistaken and clinically harmful. Appeals to personal responsibility often misrepresent the nature of addiction and overestimate the degree of knowledge and control individuals possess when harmful drinking patterns begin and escalate. Early onset of alcohol use, trauma, and psychiatric comorbidity frequently constrain the range of meaningful options available long before transplantation becomes relevant. When these histories are treated primarily as evidence of blameworthy behavior, stigma is reinforced and patients may have fewer incentives to be honest about relapse risk or struggles in treatment. The article examines several influential arguments that defend the use of responsibility in transplant allocation and explains why they fail in practice. It then proposes an alternative framework. Allocation should rely on forward‐looking criteria that are relevant to clinical outcomes and fairness, including medical urgency, expected benefit, engagement in treatment, reliability in follow‐up care, and the presence of social support. These considerations can be assessed more transparently than retrospective judgments about deservingness and avoid penalizing patients for circumstances that contributed to their illness. The article concludes by considering the implications for transplant committees. Policies should reward engagement in care and support recovery rather than rely on retrospective moral judgments about past behavior. Doing so strengthens trust between clinicians and patients, improves adherence to treatment, and allocates a scarce resource on grounds that are ethically relevant to the success of transplantation.
- Open Access
- 1 December 2025
- Published by Elmer Press, Inc. in AI in Clinical Medicine
- Vol. 1, e12
Evaluating ChatGPT-5o as a Clinical Decision-Support Tool in Inflammatory Bowel Disease: A Pilot Study of Guideline Adherence and Clinical Agreement
Background: Inflammatory bowel disease (IBD) presents complex management challenges. While care is guided by expertise and guidelines, artificial intelligence (AI) is being explored as an adjunct. This study evaluates ChatGPT-5o’s ability to provide IBD recommendations by comparing its outputs with real-world decisions and European Crohn’s and Colitis Organisation (ECCO) guidelines. Methods: We performed a retrospective analysis of 19 anonymized IBD cases spanning initial and complicated disease. ChatGPT-5o generated management recommendations, which were compared with clinician treatments and ECCO guidelines across seven therapeutic domains (5-aminosalicylic acid (5-ASA), steroids, antibiotics, thiopurines, anti-tumor necrosis factor (TNF), anti-integrins, anti-interleukin-23 (IL-23)) plus diagnostic workup, symptom management, surgical consultation, and monitoring. Agreement was quantified using Cohen’s Kappa. Results: ChatGPT-5o showed perfect agreement (κ = 1.000) with providers and/or guidelines for antibiotics, diagnostic workup, symptom management, surgical consultation, monitoring, and anti-IL-23. Substantial agreement (κ ≈ 0.6 - 0.8) was observed for 5-ASA and steroids. Moderate to fair agreement (κ ≈ 0.3 - 0.5) occurred for anti-TNF and anti-integrins, reflecting variability in complex scenarios. Thiopurines demonstrated the lowest concordance, with none-to-slight agreement in human-AI comparisons but higher alignment of ChatGPT-5o with ECCO, suggesting evolving practice patterns and safety considerations. Conclusions: ChatGPT-5o closely aligns with clinicians and ECCO guidelines in multiple standardized domains, supporting its potential as a decision-support tool to enhance guideline adherence and broaden access to IBD expertise. Variability in biologic selection and thiopurine use underscores the need for expert oversight and patient-specific judgment. Prospective studies should assess longitudinal outcomes and integration strategies to ensure safe, patient-centered deployment.
- 1 December 2025
- Published by Elmer Press, Inc. in AI in Clinical Medicine
- Vol. 1, e12
Open AccessEvaluating ChatGPT-5o as a Clinical Decision-Support Tool in Inflammatory Bowel Disease: A Pilot Study of Guideline Adherence and Clinical Agreement
Background: Inflammatory bowel disease (IBD) presents complex management challenges. While care is guided by expertise and guidelines, artificial intelligence (AI) is being explored as an adjunct. This study evaluates ChatGPT-5o’s ability to provide IBD recommendations by comparing its outputs with real-world decisions and European Crohn’s and Colitis Organisation (ECCO) guidelines. Methods: We performed a retrospective analysis of 19 anonymized IBD cases spanning initial and complicated disease. ChatGPT-5o generated management recommendations, which were compared with clinician treatments and ECCO guidelines across seven therapeutic domains (5-aminosalicylic acid (5-ASA), steroids, antibiotics, thiopurines, anti-tumor necrosis factor (TNF), anti-integrins, anti-interleukin-23 (IL-23)) plus diagnostic workup, symptom management, surgical consultation, and monitoring. Agreement was quantified using Cohen’s Kappa. Results: ChatGPT-5o showed perfect agreement (κ = 1.000) with providers and/or guidelines for antibiotics, diagnostic workup, symptom management, surgical consultation, monitoring, and anti-IL-23. Substantial agreement (κ ≈ 0.6 - 0.8) was observed for 5-ASA and steroids. Moderate to fair agreement (κ ≈ 0.3 - 0.5) occurred for anti-TNF and anti-integrins, reflecting variability in complex scenarios. Thiopurines demonstrated the lowest concordance, with none-to-slight agreement in human-AI comparisons but higher alignment of ChatGPT-5o with ECCO, suggesting evolving practice patterns and safety considerations. Conclusions: ChatGPT-5o closely aligns with clinicians and ECCO guidelines in multiple standardized domains, supporting its potential as a decision-support tool to enhance guideline adherence and broaden access to IBD expertise. Variability in biologic selection and thiopurine use underscores the need for expert oversight and patient-specific judgment. Prospective studies should assess longitudinal outcomes and integration strategies to ensure safe, patient-centered deployment.
- 12 February 2025
- Published by Wiley in Journal of Surgical Oncology
- Vol. 131 (8) , 1562-1570
Assessment of Challenging Oncologic Cases: A Comparative Analysis Between ChatGPT, Gemini, and a Multidisciplinary Tumor Board
Introduction: Since its introduction in 2022, public‐access conversational AI, exemplified by ChatGPT and Gemini, has been increasingly utilized in medical decision‐making, though its impact is questionable. This study aims to evaluate its efficacy in assessing complex oncologic cases compared to a multidisciplinary tumor board (MTB) comprising experts from various specialties.Methods: A 2‐year retrospective analysis was conducted on 98 oncological cases at a reference medical center in Mexico City. A MTB comprising surgical oncologists, medical oncologists, radio‐oncologists, pathologists, among others, reviewed and discussed each case to determine management strategies. We evaluated four key decision points, dichotomized as either affirmative or negative: the need for new imaging studies, radiation therapy, chemotherapy, and surgery. Comprehensive medical documentation accompanied each case. We then compared AI's decisions with those of the MTB using the same criteria and conducted a Cohen's Kappa test to assess agreement.Results: Agreement between ChatGPT (4o) and Gemini (1.5 Flash), and the MTB ranged from none to slight for additional imaging studies (Gemini: κ = 0.100, p = 0.087; ChatGPT 4o: κ = 0.024, p = 0.592) and chemotherapy (Gemini: κ = 0.089, p = 0.316; ChatGPT 4o: κ = 0.336, p = 0.001). Moderate agreement was observed for decisions regarding surgery (Gemini: κ = 0.194, p = 0.046; ChatGPT 4o: κ = 0.467, p = < 0.001) and radiotherapy (Gemini: κ = 0.214, p = 0.012; ChatGPT 4o: κ = 0.525, p = < 0.001).Conclusions: Both ChatGPT and Gemini showed moderate agreement with the multidisciplinary tumor board on decisions regarding surgery and radiotherapy. ChatGPT also showed moderate agreement in chemotherapy, but further assessment is needed for other interventions. ChatGPT proved to be superior to Gemini in most key points. The potential of these public access AI in oncology warrants continued exploration to refine its utility in clinical practice.
- 12 February 2025
- Published by Wiley in Journal of Surgical Oncology
- Vol. 131 (8) , 1562-1570
Assessment of Challenging Oncologic Cases: A Comparative Analysis Between ChatGPT, Gemini, and a Multidisciplinary Tumor Board
Introduction: Since its introduction in 2022, public‐access conversational AI, exemplified by ChatGPT and Gemini, has been increasingly utilized in medical decision‐making, though its impact is questionable. This study aims to evaluate its efficacy in assessing complex oncologic cases compared to a multidisciplinary tumor board (MTB) comprising experts from various specialties.Methods: A 2‐year retrospective analysis was conducted on 98 oncological cases at a reference medical center in Mexico City. A MTB comprising surgical oncologists, medical oncologists, radio‐oncologists, pathologists, among others, reviewed and discussed each case to determine management strategies. We evaluated four key decision points, dichotomized as either affirmative or negative: the need for new imaging studies, radiation therapy, chemotherapy, and surgery. Comprehensive medical documentation accompanied each case. We then compared AI's decisions with those of the MTB using the same criteria and conducted a Cohen's Kappa test to assess agreement.Results: Agreement between ChatGPT (4o) and Gemini (1.5 Flash), and the MTB ranged from none to slight for additional imaging studies (Gemini: κ = 0.100, p = 0.087; ChatGPT 4o: κ = 0.024, p = 0.592) and chemotherapy (Gemini: κ = 0.089, p = 0.316; ChatGPT 4o: κ = 0.336, p = 0.001). Moderate agreement was observed for decisions regarding surgery (Gemini: κ = 0.194, p = 0.046; ChatGPT 4o: κ = 0.467, p = < 0.001) and radiotherapy (Gemini: κ = 0.214, p = 0.012; ChatGPT 4o: κ = 0.525, p = < 0.001).Conclusions: Both ChatGPT and Gemini showed moderate agreement with the multidisciplinary tumor board on decisions regarding surgery and radiotherapy. ChatGPT also showed moderate agreement in chemotherapy, but further assessment is needed for other interventions. ChatGPT proved to be superior to Gemini in most key points. The potential of these public access AI in oncology warrants continued exploration to refine its utility in clinical practice.
- 3 December 2024
- Published by BMJ in Journal of Medical Ethics
- Vol. 51 (3) , 170-171
Reassessing the role of informed decision-making in cardiac xenotransplantation
- 3 December 2024
- Published by BMJ in Journal of Medical Ethics
- Vol. 51 (3) , 170-171
Reassessing the role of informed decision-making in cardiac xenotransplantation